Trump Signs Executive Order Fast-Tracking Psychedelic Drug Approvals for Mental Health
On April 18, 2026, President Donald Trump signed an executive order accelerating FDA reviews for psychedelic drugs like psilocybin and ibogaine to treat mental health disorders, particularly PTSD in veterans. The initiative allocates $50 million in federal funds and mandates fast-track approvals, marking a significant shift in U.S. drug policy. Joined by Health Secretary Robert F. Kennedy Jr. and other advocates, the administration aims to address the national mental health crisis and high veteran suicide rates by mainstreaming these previously restricted therapeutic substances.
Editorial summary awaiting refresh
Cross-source coverage
Wire timeline
Trump Signs Executive Order to Fast-Track Psychedelic Drug Research
US President Donald Trump signed an executive order on Saturday aimed at accelerating research into psychedelic drugs, such as psilocybin and LSD, for treating mental health conditions. The order seeks to remove bureaucratic hurdles and improve data sharing between the FDA and the Department of Veterans Affairs. It also facilitates the fast rescheduling of any psychedelic drugs that receive FDA approval, potentially moving them from high-abuse classifications to allowed medical use. The signing ceremony featured Health Secretary Robert F. Kennedy Jr. and podcaster Joe Rogan, both advocates for expanded access. While the order does not immediately legalize therapeutic use or require law enforcement reclassification, it responds to growing demand for alternative treatments for veterans suffering from trauma, anxiety, and depression. Trump highlighted ibogaine during the event, citing significant symptom reduction in patients, though he acknowledged potential risks like heart damage. This move marks a significant shift in federal policy regarding psychedelics, aiming to unlock their potential benefits while navigating existing regulatory frameworks and safety concerns associated with these substances.
News | Euronews RSSTrump Signs Executive Order to Promote Hallucinogen Research for Veteran PTSD
On April 18, 2026, U.S. President Donald Trump signed an executive order aimed at accelerating research into hallucinogens for the treatment of severe mental illnesses, particularly post-traumatic stress disorder (PTSD) in military veterans. The order highlights substances like ibogaine, citing clinical studies that suggest significant alleviation of depression and anxiety symptoms. Trump emphasized the urgency of addressing the mental health crisis among former soldiers, noting that suicide rates among veterans since the 9/11 attacks have far exceeded combat casualties. Describing veteran suicide as a national tragedy, the administration seeks to fast-track the approval of these potentially effective treatments, which have historically been restricted due to abuse risks. During the announcement, Trump referenced data showing 80 to 90 percent symptom improvement in trials and made light-hearted remarks about his own stress levels. This policy shift represents a significant move in U.S. healthcare and drug regulation, aiming to provide new therapeutic options for those suffering from the emotional scars of wars in Afghanistan and Iraq.
asahiTrump Signs Executive Order Promoting Hallucinogen Research for Veteran PTSD
On April 18, 2026, U.S. President Donald Trump signed an executive order aimed at accelerating research into hallucinogens for the treatment of severe mental illnesses, particularly post-traumatic stress disorder (PTSD) in military veterans. The order highlights substances like ibogaine, citing clinical studies that suggest significant alleviation of depression and anxiety symptoms. Trump emphasized the urgency of addressing the mental health crisis among former soldiers, noting that suicide rates among veterans since the 9/11 attacks have far exceeded combat deaths. While acknowledging the historical illegal status of most hallucinogens due to abuse risks, the administration intends to fast-track the approval of effective treatments. During the announcement, Trump referenced high efficacy rates from recent trials and made light-hearted remarks about his own stress levels. This policy shift represents a significant move in U.S. healthcare strategy, targeting the lingering emotional scars from conflicts in Afghanistan and Iraq. The initiative seeks to balance medical innovation with regulatory oversight to provide relief for those suffering from service-related trauma.
asahiTrump Signs Executive Order to Promote Hallucinogen Research for Veteran PTSD
On April 18, 2026, U.S. President Donald Trump signed an executive order aimed at accelerating research into hallucinogens for the treatment of severe mental illnesses, particularly post-traumatic stress disorder (PTSD) among military veterans. The order highlights substances like ibogaine, citing clinical studies that demonstrate their effectiveness in alleviating symptoms of depression and anxiety in 80 to 90 percent of cases. Although most hallucinogens remain illegal in the United States due to abuse risks, the administration seeks to fast-track the approval of appropriate therapeutic drugs. Trump emphasized the urgency of addressing the mental health crisis among former soldiers, noting that suicide rates among veterans since the 9/11 attacks have significantly exceeded combat fatalities. Describing veteran suicide as a national tragedy, the President framed the initiative as a critical step toward healing emotional scars from the wars in Afghanistan and Iraq. During the announcement, Trump also made light-hearted remarks about the potential personal benefits of such treatments, underscoring the administration's commitment to exploring alternative medical solutions for intractable psychological conditions affecting the military community.
asahiTrump Signs Executive Order to Promote Hallucinogen Research for Veteran PTSD
On April 18, 2026, U.S. President Donald Trump signed an executive order aimed at accelerating research into hallucinogens for the treatment of severe mental illnesses, particularly post-traumatic stress disorder (PTSD) in military veterans. The order highlights substances like ibogaine, citing clinical studies that suggest significant alleviation of depression and anxiety symptoms. Trump emphasized the urgency of addressing the mental health crisis among former soldiers, noting that suicide rates among veterans since the 9/11 attacks have far exceeded combat casualties. Describing veteran suicide as a national tragedy, the administration intends to fast-track the approval of effective treatments despite the historical illegal status of many hallucinogens due to abuse risks. During the announcement, Trump referenced high efficacy rates from recent trials and made light-hearted remarks about his own stress levels. This policy shift marks a significant move in U.S. healthcare strategy, focusing on alternative therapies for the emotional scars left by the Wars in Afghanistan and Iraq. The initiative seeks to balance regulatory caution with the immediate need for effective mental health interventions for those who served in the War on Terror.
asahiTrump Signs Executive Order to Promote Hallucinogen Research for Veteran PTSD
On April 18, 2026, U.S. President Donald Trump signed an executive order aimed at accelerating research into hallucinogens for the treatment of severe mental illnesses, particularly post-traumatic stress disorder (PTSD) in military veterans. The order highlights substances like ibogaine, citing clinical studies that suggest they can significantly alleviate symptoms of depression and anxiety. Trump emphasized the urgency of addressing the mental health crisis among former soldiers, noting that suicide rates among veterans since the 9/11 attacks have far exceeded combat casualties. Describing veteran suicide as a national tragedy, the administration intends to fast-track the approval of effective treatments despite the historical illegal status of many hallucinogens due to abuse risks. During the announcement, Trump referenced data showing 80 to 90 percent symptom relief in trials and made light-hearted remarks about his own stress levels. This policy shift marks a significant change in the federal approach to psychedelic drugs, prioritizing their therapeutic potential for those who served in conflicts such as the wars in Afghanistan and Iraq.
asahiTrump Signs Executive Order Fast-Tracking Psychedelic Drug Reviews for Mental Health
On April 18, 2026, President Donald Trump signed an executive order aimed at accelerating the regulatory review of psychedelic drugs for treating mental health disorders such as depression, anxiety, and PTSD. The order directs $50 million in federal funds to enhance accessibility and mandates the Food and Drug Administration (FDA) to fast-track approvals for substances like psilocybin and ibogaine. During the Oval Office ceremony, Trump was joined by Health and Human Services Secretary Robert F. Kennedy Jr., Dr. Mehmet Oz, former Navy SEAL Marcus Luttrell, and podcast host Joe Rogan. The administration framed this initiative as a critical response to the national mental health crisis, citing statistics on serious mental illness among American adults. FDA Commissioner Mary Makary announced that national priority vouchers would be issued to expedite the review process, potentially approving these treatments within weeks. This move marks a significant shift from previous decades where research was halted, aligning with recent studies demonstrating the efficacy of psychedelics in alleviating psychiatric conditions. The event highlights a collaborative effort between the government, medical experts, and advocates to mainstream psychedelic therapy.
npr